Learn
Learn
Six explainers on the science this company works in — written for clinicians and investors, cited to the FDA labels, professional-society guidance and primary literature they rest on.
6 explainersLast updated September 16, 2026
Educational material about approved, prescription medicines and how candidates are evaluated. Not medical advice, and not a treatment recommendation.
Explainers
- What is targeted radiopharmaceutical therapy?The modality in clinical terms: ligand, radionuclide, the theranostic pair, and the approved medicines as worked examples.10 min read
- Why off-target binding matters more for a radiopharmaceuticalRadiation does not need to bind to do damage — which changes what off-target means, and which tissues the labels watch.10 min read
- Biodistribution and dosimetry, explainedWhere the molecule goes, what a PET image measures, and why absorbed dose to healthy organs is tracked at all.11 min read
- Kd, pKd and IC50: binding affinity explainedWhat Kd and pKd are, why IC50 is not the same thing, and what a predicted-affinity ranking can and cannot tell you.11 min read
- From target to a preclinical candidateDiscovery, in-vitro binding, in-vivo imaging, IND-enabling work and the regulatory touchpoints — and where in-silico work sits.11 min read
- AI in radiopharmaceutical designWhat the models do, what the published evidence supports, and a checklist for reading any vendor's numbers — including ours.12 min read
Learn
Start with the words.
Every term these pages use is defined, with the authority behind each definition, in the glossary.
Contact
Bring us a target.
Researchers with a target to design against, investigators with a candidate to de-risk, investors asking for the pipeline data — one form reaches all three.
Laboratory bench · liquid handler and assay plates